The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase (RTK) is altered by chromosomal rearrangements in non- Hodgkin's lymphoma (NHL) and the sarcoma known as inflammatory myofibroblastic tumor (IMT) to produce constitutively active ALK fusion proteins. A direct causal relationship exists between the expression of ALK fusions and the genesis of NHL or IMT. Conversely, inhibition of ALK activity reverses the malignant phenotype experimentally. The normal functions of ALK are incompletely known, and Alk knockout mice exhibit no gross or histopathologic abnormalities. Studies of ALK signal transduction have identified several previously known kinase substrates as important in mediating ALK signaling, but the complete spectrum of substrates required for normal or oncogenic signaling by the kinase is not yet clear. Given the excellent validation of ALK as a target for directed therapies, Aim 1a of this proposal seeks to develop ATP-competitive small molecule inhibitors of ALK and to determine their specificity, toxicity and efficacy in preclinical tumor models. To provide guidance for the rational, structure-based design of ALK inhibitors, the studies in Aim 1b will determine the X-ray crystallographic structure of the apo, inactive and tris-phosphorylated, fully active ALK KD, as well as the structure of the ALK KD co- crystallized with selected inhibitors. The RTK known as leukocyte tyrosine kinase (LTK) and ALK share remarkable homology and a partially overlapping expression pattern, suggesting possible functional redundancy. To better understand the function of these kinases in growth and development and assess the consequences of their simultaneous inhibition (as may occur pharmacologically even with highly specific ATP-competitive ALK inhibitors), mice that lack both Alk and Ltk will be generated and characterized in Aim 1c. Recent ALK signaling studies have identified a novel substrate, ALK-interacting nuclear protein 3 (ANP-3), that possesses the ability to alter both apoptosis and cell cycle transit, especially mitotic entry and exit. The studies in Aim 2a will seek to determine the exact role of ANP-3 in the normal regulation of apoptotic death and the cell cycle, focusing especially on M-phase transit, and to understand the mechanism and consequences of ANP-3 deregulation by oncogenic ALK fusions. Finally, in Aim 2b, the phenotypic effects of Anp-3 inactivation in vivo on embryonic development, cell cycle integrity and apoptosis control will be assessed. These studies will improve basic understanding of normal ALK functions and the mechanisms employed by ALK fusion proteins in malignancy, while also identifying small molecule ALK inhibitors for use as basic research tools and ultimately perhaps for therapeutic applications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA069129-07
Application #
6607490
Study Section
Special Emphasis Panel (ZRG1-PTHC (01))
Program Officer
Mufson, R Allan
Project Start
1996-04-01
Project End
2007-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
7
Fiscal Year
2003
Total Cost
$326,766
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Illert, Anna Lena; Kawaguchi, Hiroyuki; Antinozzi, Cristina et al. (2012) Targeted inactivation of nuclear interaction partner of ALK disrupts meiotic prophase. Development 139:2523-34
Weiss, Joseph B; Xue, Changhui; Benice, Ted et al. (2012) Anaplastic lymphoma kinase and leukocyte tyrosine kinase: functions and genetic interactions in learning, memory and adult neurogenesis. Pharmacol Biochem Behav 100:566-74
Webb, Thomas R; Slavish, Jake; George, Rani E et al. (2009) Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 9:331-56
Li, Rongshi; Pourpak, Alan; Morris, Stephan W (2009) Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem 52:4981-5004
Jake Slavish, P; Jiang, Qin; Cui, Xiaoli et al. (2009) Design and synthesis of a novel tyrosine kinase inhibitor template. Bioorg Med Chem 17:3308-16
Kadin, Marshall E; Pinkus, Jack L; Pinkus, Geraldine S et al. (2008) Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative. Am J Surg Pathol 32:1421-6
George, Rani E; Sanda, Takaomi; Hanna, Megan et al. (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455:975-8
Li, Rongshi; Morris, Stephan W (2008) Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev 28:372-412
Bassermann, Florian; von Klitzing, Christine; Illert, Anna Lena et al. (2007) Multisite phosphorylation of nuclear interaction partner of ALK (NIPA) at G2/M involves cyclin B1/Cdk1. J Biol Chem 282:15965-72
Li, Rongshi; Xue, Liquan; Zhu, Tong et al. (2006) Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase. J Med Chem 49:1006-15

Showing the most recent 10 out of 50 publications